[1] Qazi S, et al. Global Action Plan for the Prevention and Control of Pneumonia (GAPP) Report of an informal consultation La Mainaz, Gex, France. 5–7 March 2007. WHO, 2008.
[2] Rudan I et al. Epidemiology and etiology of childhood pneumonia. Bulletin of the World Health Organization 86:408–416, 2008.
[3] Pneumonia:the forgotten killer of children. New York: United Nations Children’s Fund; 2006.
[4] Greenwood B. A global action plan for the prevention and control of pneumonia. Bulletin of the World Health Organization | May 2008, 86 (5), 322-323.
[5] Reyburn H et al. Clinical assessment and treatment in paediatric wards in the north-east of the United Republic of Tanzania. Bulletin of the World Health Organization 86 (2): 132–139, 2008
[6] Hazir T et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomized equivalency trial. Lancet; 371: 49–56, 2008.
[7] Marsh D et al. Community case management of pneumonia: at a tipping point? Bulletin of the World Health Organization 86:381–389, 2008.
[8] Dawson P et al. From research to national expansion: 20 years’ experience of community-based management of childhood pneumonia in Nepal. Bulletin of the World Health Organization 86:339–343, 2008.
[9] WHO. Home treatment for children with severe pneumonia just as effective as hospital. Press Release 9 January 2008. http://www.who.int/child_adolescent_health/news/2008/09_01/en/index.html (Last accessed May 5, 2008).
[10] Jeena P, Thea DM, Macleod MB, the APPIS Group. Failure of standard antimicrobial therapy in children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia. Bull World Health Organ 84:269-75, 2006.
[11] Jeena PM. Can the burden of pneumonia among HIV-infected children be reduced? Bulletin of the World Health Organization 86 (5):323, 2008.
[12] McNally LM et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 369: 1440–51, 2007
[13] English M. Antibiotic therapy for childhood pneumonia in an HIV endemic setting. 38th World Lung Health Conference, Cape Town, symposium on childhood pneumonia, 2007.
[14] Qazi, op. cit.
[15] Rudan op. cit.
[16] Qazi, op. cit.
[17] Zar H. Incidence, causes and outcome of pneumonia in HIV-infected African children. 38th World Lung Health Conference, Cape Town, symposium on childhood pneumonia, 2007.
[18] Zar H, Mahdi SA. Childhood pneumonia – progress and challenges. SAMJ, Vol. 96, No. 9, 2006.
[19] McNally op. cit.
[20] Jeena PM et al. Impact of HIV-1 status on the radiological presentation and clinical outcome of children with WHO defined community-acquired severe pneumonia. Arch Dis Child 92:976-9, 2007.
[21] Graham SM. HIV-related pulmonary disorders: practice issues. Annals of Tropical Paediatrics 27, 243–252, 2007.
[22] Mahdi SA et al. Vaccines to prevent pneumonia and improve child survival. Bulletin of the World Health Organization 86:365–372, 2008.
[23] Madhi SA et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 24:410-6, 2005.
[24] Madhi SA et al. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency type 1-infected children. Clin Infect Dis 31: 170-176, 2000.
[25] Zar H, Mahdi SA. Childhood pneumonia – progress and challenges. SAMJ, Vol. 96, No. 9, 2006.
[26] Graham SM et al. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. Bulletin of the World Health Organization 2008;86:349–355.
[27] Qazi, op. cit.
[28] Enarson, P et al. Implementation of an oxygen concentrator system in district hospital paediatric wards throughout Malawi. Bulletin of the World Health Organization 86:344–348, 2008.
[29] Qazi, op. cit.
[30] Zar HJ et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatr 90:119-125, 2001.
[31] Madhi SA, 2000, op. cit.
[32] McNally, op. cit.
[33] Madhi SA et al. Increased burden of respiratory viral associated severe lower respiratory tract infections in children with human immunodeficiency virus type-1. J Pediatr 2000; 137:78-84
[34] Graham SM. Non-tuberculosis opportunistic infections and other lung diseases in HIV-infected infants and children. Int J Tuberc Lung Dis 9(6):592–602, 2005.
[35] Chintu C et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 364: 1865–71, 2004.
[36] Ikeogu MO, Wolf B, Mathe S. Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Arch Dis Child 76: 124-128, 1997.
[37] Graham SM et al. Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children. Lancet 355(9201):369-73, 2000.
[38] Obaro S. Pneumocystis carinii pneumonia in Malawian children. Lancet 355: 2074-2075, 2000.
[39] Zar HJ et al. Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus. Pediatr Infect Dis J 19: 603-607, 2000.
[40] Madhi SA et al. Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin Infect Dis.;35(9):1120-6, 2002.
[41] Ruffini DD, Madhi SA. The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS 16(1):105-12, 2002.
[42] Graham SM. HIV-related pulmonary disorders: practice issues. Annals of Tropical Paediatrics 27, 243–252, 2007.
[43] McNally, op. cit.
[44] Graham SM. Prophylaxis against Pneumocystis cariniipneumonia for HIV-exposed infants in Africa. Lancet 360: 1966–68, 2002.
[45] Laufer MK et al. Observational Cohort Study of HIV-Infected African Children. The Pediatric Infectious Disease Journal 25(7): 623–627, 2006.
[46] Jeena PM. Clinical Presentation and Management of PCP and CMV pneumonia. 38th World Lung Health Conference, Cape Town, symposium on childhood pneumonia, 2007.
[47] Lucas SB et al. BMJ, 312: 335-38, 1996.
[48] Wakefield AE et al. Trans R Soc Trop Med Hyg 84: 800-802, 1990.
[49] World Health Organization, WHO Expert Consultation on Cotrimoxazole Prophylaxis in HIV Infection, draft meeting report, Geneva, 10-12 May 2005.
[50] Chintu C et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 360: 985–90, 2002.
[51] McNally, op. cit.
[52] Graham SM. Int J Tuberc Lung Dis, op. cit.
[53] Madhi SA. Clin Infect Dis, op cit.
[54] McNally, op. cit.